An updated meta-survey that was published in Our World in Data in April 2018 shares data from various mental wellness studies that indicates that people suffering from mental ailments and substance abuse range in the billions worldwide.
Similarly, WHO published information that showed that between the years 1990 and 2013, the number of people suffering from anxiety and depression increased to 615 million from 416 million, which equates to an almost 50% increment. Nearly 10% of the global population is affected, with mental illnesses making up 30% of the world’s non-fatal disease burden.
Earlier in 2018, mental health was declared to be a neglected issue by the United Nations, the press releasing stating that there could be no health without mental health.
Additionally, a landmark WHO 2016 study showed a connection in the unchartered territory between the economy and depression. The study discovered that anxiety and depression disorders cost the world as a whole nearly US $1 trillion every year yet $4 trillion was made by pharmaceutical companies to ‘treat’ these diseases.
Mental health is a global and local problem that devastates communities, destroys lives and tortures individuals and their families and the pharmaceutical therapies in the market are not helping make things better.
Most Big Pharma drugs used to treat various mental health conditions are not working to combat the diseases and are instead inducing substance dependency issues such as addiction to Xanax, Oxycodone and Percocet. Additionally, drug overdose deaths that involve synthetic opioids almost doubled between 2013-2014. More studies discovered that pharmaceutical drugs were used to commit suicide as well. This shows the myriad of issues that Big Pharma brings to the table.
This is where psychedelics come in.
The Global Drugs Survey 2018 showed that psychedelics are the safest drugs, with psilocybin being declared the safest recreational drug in the world. Psychedelics lower the risk of suicide and are impossible to overdose on. LSD was also found to be safe for use, 1/10th as harmful as liquor and was also recognized as one of the most effective treatments for helping manage cigarette and alcohol addiction.
Psychedelics have also shown their efficacy in the recent times in treating mental ailments, thereby cementing themselves as established medical facts. The effectiveness of these drugs range from MDMA-based and ayahuasca therapies being used to treat Afghanistan and Iraq U.S. war veterans who had been affected by PTSD to showing its efficacy in treating anxiety, chronic depression, OCD, lifelong addiction and insomnia.
Many have seen the videos that show the remarkable ability of cannabis extracts to reduce painful tremors caused by Parkinson’s or its ability to soothe dangerous and painful seizures in children. Some researchers believe that in the future, psychedelics might be used to treat other diseases such as diabetes and cluster headaches.
With the decades of research conducted over the years in the psychological, medical and general scientific communities, the growing interest in psychedelics from the public and the ongoing clinical studies that study the plant-based therapy for more benefits, it appears that psychedelics are here to stay.
With the Multidisciplinary Association for Psychedelic Studies and other institutions leading pioneering studies in psychedelic therapies, now is the perfect time to start normalizing psychedelics as an alternative and much safer medical therapy. Acting sensibly and collectively to alleviate mental illness suffering by completely legalizing and normalizing psychedelics use would be beneficial to millions and probably billions of people around the globe.
With psychedelics companies like Pure Extract Technologies Corp. leading the way, it won’t be long before the stigma directed at psychedelics is brought to an end and their benefits appreciated.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.